-
Maresca uncertain over Rodri's future at Man City
-
Hotter Europe isn't cooling investor fervor for stocks
-
MEXC's August 2026 Proof of Reserves Confirms User Assets Fully Backed as Reserve Ratios Remain Above 100%
-
Duplantis into pole vault final at Euros
-
Zambia suspends vote counting nationwide citing violence
-
Maresca says 'anything can happen' amid talk of Rodri move to Barcelona
-
Coe pledges court showing to defend World Athletics over Russia stance
-
Indonesian leader vows to shut over 750 'unproductive' state-owned firms
-
Stocks mixed as oil climbs, dollar drops
-
NATO jets shoot down drone in Latvian airspace: spokesperson
-
Tourists beat the heat with 'magical' Colosseum night tours
-
Wildfire forces hundreds to flee in western Germany
-
Spain extends largest nuclear plant in policy U-turn
-
Croatian wildfire forces thousands to flee, injures dozens
-
Gill says 'huge honour' to lead India in 600th Test
-
Latest developments: Europe battles wildfires
-
Brazilian police recover Matisse works stolen in 2025
-
Is a new conflict brewing in northern Ethiopia?
-
Exiled Putin critic says push for peace put him in danger
-
UK firefighters 'under pressure' as multiple blazes rage
-
EU to study potential vaccine for Lyme disease: companies
-
ARKBRIDGE Reaches 50,000 Clients and Launches New Referral Rewards Program
-
Colombia vows to find all missing quake victims as rescue hopes fade
-
New wildfire forces evacuation of 500 people in France
-
Farage wins UK by-election as Count Binface claims 'moral victory'
-
ट्रोजन: एक अधिक खतरनाक राजनीतिक युग के लिए विशेष सुरक्षा
-
TROJAN: 더욱 위험해진 정치 시기를 위한 특별 보호 조치
-
『TROJAN』:政治情勢がより危険になる時代に向けた特別な保護策
-
《特洛伊木馬》:在政治局勢日趨險惡的時代,提供特別保護
-
برنامج «TROJAN»: حماية خاصة في ظل أوقات سياسية أكثر خطورة
-
TROJAN: спеціальний захист для більш небезпечних політичних часів
-
TROJAN: Special protection for a more perilous political era
-
Thai schools step up security after deadly shooting
-
Tanzid makes history as Bangladesh dominate first Australia Test
-
Thousands stranded as heavy rain kills at least four in Japan
-
Indonesia to close more than 750 state-owned enterprises
-
McIntosh bounces back with 400m medley win at Pan Pacs
-
US backs Japan over Putin trip to disputed islands
-
Farage declares victory as count still underway in UK by-election
-
'I want to be Eala': Philippine sensation sparks tennis boom at home
-
Australia probes three near-misses at Sydney Airport
-
US says lower oil prices, not Iran's nuclear program, are now top priority in war
-
Classy Tanzid puts Bangladesh in firm charge against Australia
-
Most Asian stocks track Wall St record as US data ease rate fears
-
Schwarber smacks two homers to power Philles' MLB Field of Dreams win
-
China's viral 'spicy strips' take a bite of global snack market
-
Pakistan's date workers toil through rising heat
-
Shelton does the double in Canada
-
New trend of injecting banned peptides to 'optimise' body
-
'Shock' gloves for US immigration agents fuel potential abuse fears
UK researchers cure man who had Covid for 411 days
British researchers announced Friday they have cured a man who was continually infected with Covid for 411 days by analysing the genetic code of his particular virus to find the right treatment.
Persistent Covid infection -- which is different to long Covid or repeated bouts of the disease -- occurs in a small number of patients with already weakened immune systems.
These patients can test positive for months or even years with the infection "rumbling along the whole time", said Luke Snell, a physician specialising in infectious diseases at Guy's and St Thomas' NHS Foundation Trust.
The infections can pose a serious threat because around half of patients also have persistent symptoms such as lung inflammation, Snell told AFP, adding that much remains unknown about the condition.
In a new study published in the journal Clinical Infectious Diseases, a team of researchers at Guy's and St Thomas' NHS Foundation Trust and King's College London describe how a 59-year-old man finally overcame his infection after more than 13 months.
The man, who has a weakened immune system due to a kidney transplant, caught Covid in December 2020 and continued to test positive until January this year.
To discover whether he had contracted Covid numerous times or if it was one persistent infection, the researchers used a rapid genetic analysis with nanopore sequencing technology.
The test, which can deliver results in as little as 24 hours, showed the man had an early B.1 variant which was dominant in late 2020 but has since been replaced by newer strains.
Because he had this early variant, the researchers gave him a combination of the casirivimab and imdevimab monoclonal antibodies from Regeneron.
Like most other antibody treatments, the treatment is no longer widely used because it is ineffective against newer variants such as Omicron.
But it successfully cured the man because he was battling a variant from an earlier phase of the pandemic.
- Resistant to treatment -
"The very new variants that are increasing in prevalence now are resistant to all the antibodies available in the UK, the EU and now even the US," Snell said.
The researchers used several such treatments to try to save a seriously ill 60-year-old man in August this year who had been infected since April.
However none worked.
"We really thought he was going to die," Snell said.
So the team crushed up two antiviral treatments not previously used together -- Paxlovid and remdesivir -- and administered them to the unconscious patient via a nasal tube, according to a non-peer-reviewed preprint study on the website ResearchSquare.
"Miraculously he cleared and perhaps this is now the avenue for how we treat these very difficult persistent infections," Snell said, emphasising that this treatment may not translate for normal Covid cases.
At the ECCMID conference in April, the team announced the longest-known persistent infection in a man who tested positive for 505 days before his death.
That "very sad case" came earlier in the pandemic, Snell said, adding that he was grateful there were now so many more treatment options available.
N.Shalabi--SF-PST